🇺🇸 FDA
Pipeline program

CID-103

CASI-CID-103-201

Phase 2 small_molecule active

Quick answer

CID-103 for Chronic Immune Thrombocytopenia is a Phase 2 program (small_molecule) at CASI Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
CASI Pharmaceuticals
Indication
Chronic Immune Thrombocytopenia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials